Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs James Hardie Industries plc. Ordinary Shares (JHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs James Hardie Industries plc. Ordinary Shares — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.3 (market cap $4.03B), while James Hardie Industries plc. Ordinary Shares trades at $24.56 (market cap $14.27B). The key difference: James Hardie Industries plc. Ordinary Shares is far larger — about 3.5× Indivior Pharmaceuticals Inc. Common Stock's market cap, and James Hardie Industries plc. Ordinary Shares is more actively traded (8,815,886 versus 2,781,171). Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and James Hardie Industries plc. Ordinary Shares for 6 Days on average.
| INDV | JHX | |
|---|---|---|
Market Cap | $4.03B | $14.27B |
Volume | 2,781,171 | 8,815,886 |
Sector | Health | Basic Materials |
52-Week High | $41.83 | $31.08 |
52-Week Low | $24.09 | $16.69 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $4.32B | $18.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
James Hardie Industries (JHX) trades at $24.67, down 0.36% with a bearish technical outlook. The stock shows mixed fundamentals with a high P/E ratio of 112.14 but strong revenue growth from $3.88B to $5.4B projected. Recent earnings beat expectations in Q2 2026, and the company completed strategic divestitures including the $980M Fermacell sale to Holcim. Analyst sentiment remains positive with 70.59% buy ratings and a $34 consensus price target representing 38% upside potential.
JHX presents a growth story with expanding revenues but faces profitability compression as net margins decline from 10.93% to 2.69%. The stock's high valuation multiples require strong execution to justify. Key risks include integration challenges from recent acquisitions, rising debt levels, and housing market sensitivity. Institutional ownership shows mixed signals with State Street reducing its position while short interest increased 47.8% in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About James Hardie Industries plc. Ordinary Shares
James Hardie manufactures fiber cement products for residential and commercial construction. Its portfolio includes exterior siding, interior boards, and other building materials.
Read more on JHX →
